it.euronews.com
EU Drug Shortages Reach Record Levels in 2023-2024
A European Court of Auditors report reveals that shortages of 136 essential medicines reached record levels in the EU in 2023 and 2024, impacting 21 member states and driven by factors like increased demand, production delays, and high energy costs.
- What factors contributed to the increased drug shortages in the EU?
- The shortages are attributed to increased demand, production delays, capacity issues, and high energy costs. The report highlights that production costs in the EU are 20-40% higher than in Asia, and the EU's significant reliance on Asia for pharmaceutical ingredients (70% of active ingredients and 79% of biochemicals) exacerbates the problem.
- What are the key findings of the European Court of Auditors report on EU drug shortages?
- The report reveals that shortages of 136 essential medicines in the EU reached record levels in 2023 and 2024, with 48 and 46 critical shortages respectively. 21 of 27 member states reported critical shortages from the start of 2024 to October 2024, with Belgium, Spain, and France experiencing the most significant shortages.
- What are the implications of inconsistent reporting and storage practices among EU countries regarding drug shortages?
- Inconsistent reporting methods across EU countries hinder accurate comparisons and effective responses to shortages. Disparities in notification timelines (e.g., four months in Italy vs. immediate notification for some drugs in Austria) and storage requirements (e.g., six weeks in Denmark vs. six months in Germany) complicate efforts to manage and mitigate future shortages.
Cognitive Concepts
Framing Bias
The report's framing is largely neutral, presenting the facts of the drug shortages without overtly advocating for any particular solution or assigning blame. The headline and introduction clearly state the problem of widespread drug shortages in the EU. While the report highlights the severity of the issue by mentioning record-high shortage levels in 2023 and 2024, it avoids sensationalism and focuses on presenting factual data.
Language Bias
The language used is mostly neutral and objective. Terms like "critical shortages" and "record levels" accurately reflect the situation's severity without resorting to emotional or exaggerated language. The inclusion of direct quotes from an Eca representative adds credibility and avoids editorial bias.
Bias by Omission
The report could benefit from including information about the specific types of drugs in short supply and their impact on particular patient groups. This would provide a more nuanced understanding of the consequences of the shortages. Additionally, a discussion of potential long-term solutions and policy responses would strengthen the analysis. The omission of these elements may be due to space constraints or the report's intended scope.
Sustainable Development Goals
The article directly addresses the shortage of essential medicines in the EU, impacting access to healthcare and potentially leading to negative health outcomes. The report highlights record levels of critical shortages in 2023 and 2024, affecting 21 out of 27 member states. This directly undermines SDG 3, which aims to ensure healthy lives and promote well-being for all at all ages. The factors contributing to the shortages, such as increased demand, production delays, and rising energy costs, further complicate efforts to achieve this goal. The unequal reporting and stockpiling mechanisms across EU countries also hinder effective solutions.